Ibogaine is a Class C controlled substance in New Zealand under the Misuse of Drugs Act 1975, making its possession, supply, and manufacture illegal without explicit governmental authorisation. Last verified: April 2026.

Current Legal Status

Ibogaine is listed as a Class C controlled substance under Schedule 3 of the Misuse of Drugs Act 1975. This classification places ibogaine alongside other substances deemed to pose a moderate risk of harm. There are no approved medical or therapeutic indications for ibogaine in New Zealand, and the country's medicines regulator — Medsafe — has not approved any ibogaine-containing product for human use.

The key penalties under the Misuse of Drugs Act 1975 for Class C substances are:

  • Possession (first offence): Up to 3 months imprisonment or a fine not exceeding NZD $500.
  • Supply or manufacture: Maximum penalty of 3 years imprisonment. Note that this is the Class C maximum — the higher 8-year maximum applies to Class B substances and does not apply to ibogaine.
  • Importation: Treated as supply; carries the same maximum penalty of 3 years imprisonment.

No Religious or Medical Exemptions: Unlike some jurisdictions, New Zealand does not provide recognised religious or ceremonial carve-outs for ibogaine use. There is no compassionate access scheme or clinical trial pathway currently open to the public for ibogaine. Ministry of Health approvals for unapproved medicines under the Medicines Act 1981 exist in theory but have not been publicly applied to ibogaine.

The Psychoactive Substances Act 2013 is a separate regulatory framework that governs novel psychoactive substances, but ibogaine — as a specifically scheduled substance under the Misuse of Drugs Act 1975 — falls outside its scope and remains subject to criminal penalties.

Treatment Centers

There are no legal ibogaine treatment centers operating in New Zealand. Because ibogaine is a Class C controlled substance with no approved therapeutic use, no clinic, medical practice, or retreat can lawfully administer ibogaine to patients within New Zealand's borders.

New Zealanders seeking ibogaine-assisted treatment must travel to jurisdictions where it is legally available or unscheduled. For a directory of international clinics operating in legal jurisdictions, see our full clinic directory.

Not a Treatment Destination: New Zealand is not an ibogaine treatment destination. Individuals travelling to New Zealand specifically for ibogaine treatment will not find lawful options and risk criminal penalties.

How People Access Ibogaine in New Zealand

The following reflects factual patterns that have been reported or are known to occur. This is not a recommendation or endorsement of any illegal activity.

  • International travel: Some New Zealanders travel to countries where ibogaine treatment is legally available — most commonly Mexico, Jamaica, Portugal, or South Africa — to undergo treatment at licensed or operating clinics. Returning to New Zealand after treatment carries no specific legal consequence in itself, but importing any ibogaine substance would be illegal.
  • Underground or informal settings: Anecdotal reports indicate that some ibogaine use occurs in informal, unregulated settings within New Zealand. This carries significant legal risk under the Misuse of Drugs Act 1975 as well as serious medical risks given the absence of clinical oversight, screening, or cardiac monitoring.
  • Grey-market importation: Some individuals attempt to import ibogaine or iboga-containing products through international postal services. This constitutes importation and supply under New Zealand law and is subject to criminal penalties.

Anyone considering ibogaine treatment is strongly encouraged to consult a licensed attorney and a qualified medical professional before taking any action.

Recent Legal Developments

Over the past two years, there have been no legislative changes to ibogaine's Class C status in New Zealand. The substance remains firmly scheduled, and no government consultation or reform process specifically targeting ibogaine has been announced.

However, broader psychedelic policy reform has gained modest momentum in New Zealand:

  • In 2023, the New Zealand Drug Foundation and other harm reduction organisations continued to advocate for drug law reform, including reclassification of certain substances, though ibogaine has not been a primary focus of those campaigns.
  • The global expansion of ibogaine research — particularly studies examining ibogaine for opioid use disorder and PTSD, including research programmes in the United States and Europe — has raised awareness among some New Zealand clinicians and policymakers, but no formal regulatory review has been initiated.
  • Medsafe has not received or granted any application for ibogaine as an unapproved medicine under Section 29 of the Medicines Act 1981 that has been publicly disclosed.

Watch This Space: As international clinical evidence accumulates — particularly from Phase 2 and Phase 3 trials in other jurisdictions — there is a possibility that New Zealand regulators may in future consider a compassionate access or rescheduling pathway. Currently, however, no such process is underway.

Risks of Seeking Treatment in New Zealand

Because no legal treatment infrastructure exists in New Zealand, anyone who undergoes ibogaine administration within the country does so entirely outside any regulated framework. This creates compounding risks:

  • No clinical screening: Legal ibogaine clinics in jurisdictions like Mexico and Portugal typically require cardiac screening (ECG), liver function tests, and full medication review before treatment. Informal settings in New Zealand are very unlikely to provide this, significantly increasing the risk of fatal cardiac arrhythmia — ibogaine's most serious documented risk.
  • No quality control: Ibogaine obtained through informal or grey-market channels cannot be verified for purity, concentration, or the absence of adulterants. Dose errors in ibogaine are potentially fatal.
  • No medical emergency backup: Ibogaine treatment requires access to resuscitation equipment and personnel trained in cardiac emergency management. Informal settings cannot guarantee this.
  • Criminal liability: Both the person administering ibogaine and the person receiving it may face criminal charges under the Misuse of Drugs Act 1975. The provider faces greater exposure under supply provisions.
  • No legal recourse: If harm occurs in an illegal setting, the ability to seek compensation or accountability is severely limited.

Medical Warning: Ibogaine carries a real risk of fatal cardiac arrhythmia, particularly for individuals with undiagnosed heart conditions or those taking QT-prolonging medications. Medical screening before any ibogaine exposure is not optional — it is a clinical safety requirement. Do not attempt ibogaine outside a medically supervised setting.

Frequently Asked Questions

No. Ibogaine is a Class C controlled substance under Schedule 3 of the Misuse of Drugs Act 1975. Possession, supply, manufacture, and importation are all criminal offences. There are no approved medical uses, no licensed clinics, and no exemptions currently available to the general public.
For a first possession offence involving a Class C substance, the maximum penalty under the Misuse of Drugs Act 1975 is 3 months imprisonment or a fine of up to NZD $500. Supply or importation carries a maximum of 3 years imprisonment. These are statutory maximums; actual sentences vary by circumstance and judicial discretion.
No. There are no legal ibogaine treatment clinics operating anywhere in New Zealand. Ibogaine has no approved therapeutic indication under New Zealand law, and no clinic may lawfully administer it to patients. New Zealanders who wish to access ibogaine treatment must travel to a jurisdiction where it is legally available. See our clinic directory for options in legal jurisdictions.
No. Importing ibogaine into New Zealand — including bringing it back after treatment overseas — constitutes importation of a Class C controlled substance and is a criminal offence under the Misuse of Drugs Act 1975, carrying a maximum penalty of 3 years imprisonment. Travelling abroad for treatment itself is not illegal, but returning with ibogaine in any form is.
There is currently no active government process to reschedule or legalise ibogaine in New Zealand. While broader drug law reform advocacy continues and international clinical research is expanding, no formal review by Medsafe or the Ministry of Health specifically addressing ibogaine has been publicly announced as of April 2026. Any change would require amendments to the Misuse of Drugs Act 1975 or a Medsafe approval process, neither of which appears imminent.
No. The Psychoactive Substances Act 2013 governs substances not already controlled under other legislation. Because ibogaine is specifically scheduled as a Class C substance under the Misuse of Drugs Act 1975, it falls under that Act's framework rather than the Psychoactive Substances Act. The stricter Misuse of Drugs Act 1975 provisions apply.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.